Page 20 - மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article LONDON, April 28, 2021 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialisation of Combogesic ® IV, the US trade name of Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine. The licensing agreement provides Hikma with exclusive rights for the sales, marketing and distribution of Combogesic ® IV in the US.  Combogesic ® IV (paracetamol 1000mg + ibuprofen 300mg solution for infusion) is a patented intravenous formulation developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals when patients cannot take a medicine orally. AFT expects to file Combogesic

United arab emiratesUnited statesUnited kingdomCity ofSteve weissSusan ringdalDavid belianUs communicationsPrnewswire hikma pharmaceuticalsPublic affairsGlobal affairsHikma pharmaceuticalsHikma pharmaceuticals united states incRiad mishlawiStrategic planningMiddle east